Elsevier

Bone

Volume 19, Issue 3, September 1996, Pages 291-298
Bone

Original article
High bone turnover is associated with low bone mass in both pre- and postmenopausal women

https://doi.org/10.1016/8756-3282(96)00201-3Get rights and content

Abstract

In 979 healthy women, aged 30–75 years, bone mass was measured by DXA in the lumbar spine and proximal femur, and by SXA in the distal forearm. Bone turnover was assessed by urinary CrossLaps (CrossLapsTM ELISA), a new assay which measures type I collagen degradation products in urine and by osteocalcin (two-site N-Mid hOsteocalcin ELISA™), a new assay which measures the N-terminal-mid fragment (1–43) as well as the intact (1–49) osteocalcin (OCN-Mid) in serum. For comparison data on urinary hydroxyproline (fU Hpr/Cr) and serum, total alkaline phosphatase were included (AP). In premenopausal women below 50 years of age, the concentrations of the biochemical markers were stable with age. At menopause CrossLapsTM and OCN-Mid increased abruptly to a level 60% and 35% above the premenopausal mean values (p < 0.001). Premenopausal women in the highest quartiles, stratified according to the concentration of CrossLapsTM and OCN-Mid corrected for height and weight, had 6%–11% lower bone mass in all regions (p < 0.01) as compared to women in the lowest quartiles. CrossLapsTM and OCN-Mid corrected for height and weight correlated with bone mass in the spine and proximal femur, r = −0.13 to r = −0.28, p < 0.05. In postmenopausal women, the difference in bone mass between the highest and lowest quartiles was 8%–14% (p < 0.001). CrossLapsTM and OCN-Mid correlated with bone mass measured in all regions, r = −0.14 to r = −0.32, p < 0.05. The correlation between bone mass and AP and fU Hpr/Cr was lower; r = −0.06 to r = −0.20 for premenopausal women, NS to p < 0.01, and r = −0.01 to r = −0.23, NS to p < 0.001 for postmenopausal women. In conclusion, the present data indicate that high bone turnover is associated with a significantly lower bone mass in not only postmenopausal, but interestingly also in premenopausal women. In consistence with previous results, we found that bone turnover increased perimenopausally and in the early menopause.

References (37)

  • K. Bjarnason et al.

    Early postmenopausal diminution of forearm and spinal bone mineral density. A crosssectional study

    Osteopor Int

    (1995)
  • J.J. Body et al.

    Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcaemia

    J Clin Endocrinol Metab

    (1992)
  • M. Bonde et al.

    Immunoassay for quantifying type I collagen degradation products in urine evaluated

    Clin Chem

    (1994)
  • M. Bonde et al.

    Applications of an enzyme immunoassay for a new marker of bone resorption (Cross-LapsTM)—Follow up on hormone replacement therapy and osteoporosis risk assessment

    J Clin Endocrinol Metab

    (1995)
  • J. Borg et al.

    Single x-ray absorptiometry: Performance characteristics and comparison with single photon absorptiometry

    Osteopor Int

    (1995)
  • C. Christiansen et al.

    Screening procedure for women at risk of developing postmenopausal osteoporosis

    Osteoporosis Int

    (1990)
  • P.D. Delmas

    Biochemical markers of bone turnover

    J Bone Miner Res (Suppl.)

    (1993)
  • P.R. Ebeling et al.

    Sensitivity of collagen cross-links and osteocalcin in detecting early menopausal changes in bone turnover

  • Cited by (78)

    • Association of higher bone turnover with risk of curve progression in adolescent idiopathic scoliosis

      2021, Bone
      Citation Excerpt :

      Recently, two histomorphometry studies with vertebra and iliac crest bone biopsies suggested higher bone turnover in AIS patients requiring surgery, which was associated with larger osteoid area, less osteocyte and more osteoblast number [9,10]. High bone turnover is speculated to contribute to low BMD [11] and significantly modulate bone microarchitecture [12]. However, it is yet unclear whether abnormal bone turnover could be associated with curve progression in AIS.

    • Associations between the serum levels of selected bone turnover markers and biological traits in nursing home women aged 80+ without inflammation. A pilot study

      2020, Experimental Gerontology
      Citation Excerpt :

      A number of national and international organizations dedicated to osteoporosis (including the International Osteoporosis Foundation (IOF), the US National Osteoporosis Foundation (NOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)) recommend using BTMs in preventing, detecting and treating osteoporosis. Generally, the correlation between the levels of BTMs and BMD in postmenopausal women is weak (Ravn et al., 1996; Garnero et al., 1996; Chung et al., 2000), as opposed to the association between BTMs and the risk of fracture independent of BMD, which is significant (Garnero, 2008; Morris et al., 2017; Ross et al., 2000). The pattern may be due to a biological variability and according to many researchers the appropriate age- and gender-specific groups

    • Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients

      2014, Bone
      Citation Excerpt :

      Our study lends support to this theory due to the fact that while osteoclast number was similar compared to baseline, bone volume as evidenced in micro-CT results (+ 1,7%/year BV/TV [29]) increased during the course of 3 years. A high bone turnover was reported to be associated with a reduced bone mass in postmenopausal women [61]. Antiresorptive treatments, bisphosphonates in particular, have been shown to decrease the overall bone turnover, incl. osteoblastic formation, secondary to the reduction in bone resorption [62,63].

    • Reference intervals of biochemical bone turnover markers for Saudi Arabian women: A cross-sectional study

      2010, Bone
      Citation Excerpt :

      The increases in markers of bone resorption tend to be greater than that of bone formation: u-CTX (by 91.2%); u-DPD (by 80.6%); u-NTX (by 72.3%); and s-TRACP-5b (by 38.5%), respectively. Several studies showed similar changes: urinary deoxypyridinolines and urinary telopeptides increased by 2-fold [42–48]. However it is uncertain whether the onset of the changes in the biochemical BTMs takes place early in the menopausal transition or before the cessation of menstruation.

    • The primary care osteoporosis risk of fracture screening (POROS) study: Design and baseline characteristics

      2010, Contemporary Clinical Trials
      Citation Excerpt :

      The World Health Organization's fracture risk assessment (FRAX) may be a useful tool to help risk stratify women with osteopenia [3–6]. Other strategies to assess the risk of bone loss and fractures in this early postmenopausal group may include measurement of bone turnover markers, such as urine N-telopeptide (NTx) [7–10]. A baseline BMD is a static assessment of the measured skeletal sites.

    View all citing articles on Scopus
    View full text